139 related articles for article (PubMed ID: 31445852)
1. Synthesis and evaluation of radioactive/fluorescent peptide probes for imaging of legumain activity.
Fuchigami T; Itagaki K; Ishikawa N; Yoshida S; Nakayama M
Bioorg Med Chem Lett; 2019 Oct; 29(19):126629. PubMed ID: 31445852
[TBL] [Abstract][Full Text] [Related]
2. Development of near-infrared fluorophore (NIRF)-labeled activity-based probes for in vivo imaging of legumain.
Lee J; Bogyo M
ACS Chem Biol; 2010 Feb; 5(2):233-43. PubMed ID: 20017516
[TBL] [Abstract][Full Text] [Related]
3. Radiofluorinated Smart Probes for Noninvasive PET Imaging of Legumain Activity in Living Subjects.
Qiu L; Li X; Lv G; Seimbille Y; Li K; Peng Y; Liu Q; Xie M; Lin J
Anal Chem; 2020 Sep; 92(17):11627-11634. PubMed ID: 32867490
[TBL] [Abstract][Full Text] [Related]
4. Design of cell-permeable, fluorescent activity-based probes for the lysosomal cysteine protease asparaginyl endopeptidase (AEP)/legumain.
Sexton KB; Witte MD; Blum G; Bogyo M
Bioorg Med Chem Lett; 2007 Feb; 17(3):649-53. PubMed ID: 17189693
[TBL] [Abstract][Full Text] [Related]
5. Peptide-based MRI contrast agent and near-infrared fluorescent probe for intratumoral legumain detection.
Chen YJ; Wu SC; Chen CY; Tzou SC; Cheng TL; Huang YF; Yuan SS; Wang YM
Biomaterials; 2014 Jan; 35(1):304-15. PubMed ID: 24120038
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of a novel legumain-cleavable colchicine prodrug with cell-specific toxicity.
Smith RL; Åstrand OA; Nguyen LM; Elvestrand T; Hagelin G; Solberg R; Johansen HT; Rongved P
Bioorg Med Chem; 2014 Jul; 22(13):3309-15. PubMed ID: 24842619
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy.
Liu C; Sun C; Huang H; Janda K; Edgington T
Cancer Res; 2003 Jun; 63(11):2957-64. PubMed ID: 12782603
[TBL] [Abstract][Full Text] [Related]
8. Characterization of TCP-1 probes for molecular imaging of colon cancer.
Liu Z; Gray BD; Barber C; Bernas M; Cai M; Furenlid LR; Rouse A; Patel C; Banerjee B; Liang R; Gmitro AF; Witte MH; Pak KY; Woolfenden JM
J Control Release; 2016 Oct; 239():223-30. PubMed ID: 27574992
[TBL] [Abstract][Full Text] [Related]
9. A protease-responsive fluorescent probe for sensitive imaging of legumain activity in living tumor cells.
Li X; Liu Q; Ye S; Wang S; Li K; Lv G; Peng Y; Qiu L; Lin J
Chem Biol Drug Des; 2019 Aug; 94(2):1494-1503. PubMed ID: 31002467
[TBL] [Abstract][Full Text] [Related]
10. Tumor targeting of MMP-2/9 activatable cell-penetrating imaging probes is caused by tumor-independent activation.
van Duijnhoven SM; Robillard MS; Nicolay K; Grüll H
J Nucl Med; 2011 Feb; 52(2):279-86. PubMed ID: 21233187
[TBL] [Abstract][Full Text] [Related]
11. In vivo near-infrared fluorescence imaging of integrin α2β1 in prostate cancer with cell-penetrating-peptide-conjugated DGEA probe.
Huang CW; Li Z; Conti PS
J Nucl Med; 2011 Dec; 52(12):1979-86. PubMed ID: 22065876
[TBL] [Abstract][Full Text] [Related]
12. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with
Ku A; Chan C; Aghevlian S; Cai Z; Cescon D; Bratman SV; Ailles L; Hedley DW; Reilly RM
Mol Pharm; 2019 Aug; 16(8):3559-3568. PubMed ID: 31242384
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of a radioiodinated 4,6-diaryl-3-cyano-2-pyridinone derivative as a survivin targeting SPECT probe for tumor imaging.
Fuchigami T; Mizoguchi T; Ishikawa N; Haratake M; Yoshida S; Magata Y; Nakayama M
Bioorg Med Chem Lett; 2016 Feb; 26(3):999-1004. PubMed ID: 26733475
[TBL] [Abstract][Full Text] [Related]
14. Legumain-cleavable 4-arm poly(ethylene glycol)-doxorubicin conjugate for tumor specific delivery and release.
Zhou H; Sun H; Lv S; Zhang D; Zhang X; Tang Z; Chen X
Acta Biomater; 2017 May; 54():227-238. PubMed ID: 28315495
[TBL] [Abstract][Full Text] [Related]
15. Utilizing the Multiradionuclide Resolving Power of SPECT and Dual Radiolabeled Single Molecules to Assess Treatment Response of Tumors.
Xu B; Shokeen M; Sudlow GP; Harpstrite SE; Liang K; Cheney PP; Edwards WB; Sharma V; Laforest R; Akers WJ; Achilefu S
Mol Imaging Biol; 2015 Oct; 17(5):671-9. PubMed ID: 25790774
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of 111In-labeled Anginex as Potential SPECT Tracer for Imaging of Tumor Angiogenesis.
Van Mourik TR; Läppchen T; Rossin R; Van Beijnum JR; Macdonald JR; Mayo KH; Griffioen AW; Nicolay K; Grüll H
Anticancer Res; 2015 Nov; 35(11):5945-54. PubMed ID: 26504018
[TBL] [Abstract][Full Text] [Related]
17. Legumain-Specific Near-Infrared Fluorescence "Turn On" for Tumor-Targeted Imaging.
Zhao Y; Hai Z; Wang H; Su L; Liang G
Anal Chem; 2018 Aug; 90(15):8732-8735. PubMed ID: 30027744
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional regulation of the legumain gene by p53 in HCT116 cells.
Yamane T; Murao S; Kato-Ose I; Kashima L; Yuguchi M; Kozuka M; Takeuchi K; Ogita H; Ohkubo I; Ariga H
Biochem Biophys Res Commun; 2013 Sep; 438(4):613-8. PubMed ID: 23942113
[TBL] [Abstract][Full Text] [Related]
19. A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain.
Stern L; Perry R; Ofek P; Many A; Shabat D; Satchi-Fainaro R
Bioconjug Chem; 2009 Mar; 20(3):500-10. PubMed ID: 19196156
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
